Last reviewed · How we verify
bupropion + lozenge
bupropion + lozenge is a Antidepressant + nicotine replacement therapy Small molecule drug developed by University of Wisconsin, Madison. It is currently FDA-approved for Smoking cessation.
Bupropion inhibits norepinephrine and dopamine reuptake to reduce nicotine cravings, while the lozenge delivers nicotine to ease withdrawal symptoms during smoking cessation.
Bupropion is a small molecule that inhibits the sodium-dependent dopamine transporter, a mechanism that may contribute to its therapeutic effects. It has been studied as a treatment for various conditions, including cigarette smoking, marijuana abuse, schizophrenia, and schizoaffective disorder, among others.
At a glance
| Generic name | bupropion + lozenge |
|---|---|
| Sponsor | University of Wisconsin, Madison |
| Drug class | Antidepressant + nicotine replacement therapy |
| Target | Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Smoking Cessation / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
Bupropion is an atypical antidepressant that blocks reuptake of norepinephrine and dopamine, reducing the rewarding effects of nicotine and decreasing cravings. The nicotine lozenge provides transdermal nicotine replacement to manage acute withdrawal symptoms. This combination approach addresses both the neurochemical basis of addiction and acute withdrawal discomfort.
Approved indications
- Smoking cessation
Common side effects
- Insomnia
- Dry mouth
- Nausea
- Headache
- Dizziness
- Hiccups (lozenge-related)
- Mouth irritation (lozenge-related)
Key clinical trials
- Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial (PHASE4)
- Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use (NA)
- Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care (PHASE4)
- Integrating Tobacco Use Cessation Into HIV Care and Treatment in Kisumu County, Kenya (PHASE4)
- Embedding Comprehensive Smoking Cessation Programs Into Community Clinics (NA)
- Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH) (PHASE4)
- Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers (PHASE4)
- Web-based Smoking Cessation Program for Tribal College Students (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bupropion + lozenge CI brief — competitive landscape report
- bupropion + lozenge updates RSS · CI watch RSS
- University of Wisconsin, Madison portfolio CI
Frequently asked questions about bupropion + lozenge
What is bupropion + lozenge?
How does bupropion + lozenge work?
What is bupropion + lozenge used for?
Who makes bupropion + lozenge?
What drug class is bupropion + lozenge in?
What development phase is bupropion + lozenge in?
What are the side effects of bupropion + lozenge?
What does bupropion + lozenge target?
Related
- Drug class: All Antidepressant + nicotine replacement therapy drugs
- Target: All drugs targeting Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors
- Manufacturer: University of Wisconsin, Madison — full pipeline
- Therapeutic area: All drugs in Smoking Cessation / Addiction Medicine
- Indication: Drugs for Smoking cessation
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing